United Therapeutics denied request to PTAB for rehearing on ‘793 patent

A post to the site of the U.S. Patent and Trademark Office stated: "Liquidia Technologies (LQDA), the "Petitioner," filed a Petition requesting an inter partes review of claims 1-8 of U.S. Patent No. 10,716,793 B2, "the ‘793 patent." United Therapeutics (UTHR), the "Patent Owner," filed a Preliminary Response… On August 11, 2021, we instituted inter partesreview of claims 1-8 of the ‘793 patent on all grounds set forth in the Petition… On July 19, 2022, we issued a Final Written Decision determining that Petitioner had proven by a preponderance of evidence that all the challenged claims were unpatentable… On August 18, 2022, Patent Owner requested rehearing and filed a request that rehearing be conducted by the Precedential Opinion Panel… For the reasons discussed below, we deny Patent Owner’s Request for Rehearing. Reference Link